期刊文献+

血清BNP水平和药物干预在脑卒中患者继发左室舒张功能不全中的临床研究

Clinical Study of Serum BNP Level and Drug Intervention in Left Ventricular Diastolic Dysfunction in Patients With Cerebral Apoplexy
下载PDF
导出
摘要 目的分析药物干预对脑卒中患者继发左室舒张功能不全的影响。方法 205例脑卒中后左室功能不全患者分为试验组和对照组。对照组103例,用ARB加β2受体阻滞剂,试验组102例在对照组基础上加用醛固酮拮抗剂,对比分析两组患者的治疗效果。结果两组患者治疗后血清BNP均下降,但试验组下降更为明显,治疗后血压较治疗前下降,LEVF及E/A值较治疗前提高,差异均具有统计学意义(P<0.05)。结论三药方案对患者及时诊断和有效治疗具有重要意义。 Objective To discuss the effect of drug intervention on left ventricular diastolic dysfunction in patients with cerebral apoplexy.Methods 205 patients with left ventricular dysfunction after stroke were divided into test group and control group, 103 cases in control group received ARB and β2-blocker, 102 cases in test group accepted ARB、β2-blocker and aldosterone antagonist. To compare and analyze treatment effect between two groups.Results After treatment, serum BNP of two groups were significantly decreased,but test group decreased more significantly. Blood pressure was decreased, LEVF and E/A were significantly increased compared with before treatment,differences had statistical significance(P 〈 0.05).ConclusionThree drug regimens for patients with timely diagnosis and effective treatment has important significance.
作者 黄华 赵虹
出处 《中国卫生标准管理》 2015年第19期79-80,共2页 China Health Standard Management
关键词 脑卒中 左室功能不全 脑钠肽 Cerebral apoplexy Left ventricular diastolic dysfunction Brain natriuretic peptide
  • 相关文献

参考文献1

二级参考文献36

  • 1李旭,孟莹,姜泊,杨希山,王卫卫,郭丹,赖卓胜,张振书.血管紧张素Ⅱ和醛固酮对肝星状细胞核因子κB信号转导通路的影响[J].中华医学杂志,2005,85(6):374-380. 被引量:11
  • 2PITT B, ZANNAD F, REMME W J, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure, Randomized Aldactone Evaluation Study Investigators[J]. N Engl J Med, 1999, 341(10): 709-717.
  • 3PITY B, REMME W, ZANNAD F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dys-function after myocardial infarction[J]. N Engl J Med, 2003, 348(14): 1309-1321.
  • 4ZANNAD F, MCMURRAY J J V, KRUM H, et al. Eplerenone in patients with systolic heart failure and mild symptoms[J]. N Engl J Med, 2011, 364(1): 11-21.
  • 5MCMURRAY J J, ADAMOPOULOS S, ANKER S D, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J, 2012, 33(14): 1787-1847.
  • 6MAK G J, LEDWIDGE M T, WATSON C ], et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone[J]. J Am Coil Cardiol,2009, 54(18) : 1674-1682.
  • 7SCHMIEDER R E, MARTUS P, KLINGBE1L A. Reversal of left ventricular hypertrophy in hypertension:a metaanaIysisof randomized double-blind studies[J]. JAMA, 1996, 275 (19) : 1507-1513.
  • 8CUSPIDI C, NEGRI F, ZANCHETTI A. Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention[J]. Vasc Health Risk Manag, 2008, 4(1): 67- 73.
  • 9STAESSEN J, LHNEN P, FAGARD R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression[J]. J Endocrinol, 1981, 91(3): 457-465.
  • 10SATO A, SARUTA T. Aldosterane escape during angiotensin- conveting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy[J]. J Int Med Res, 2001, 29(1): 13-21.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部